Potential treatment of osteoarthritis by gene therapy

Christopher H Evans, P. D. Robbins

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Recent advances in understanding the biology of osteoarthritis have allowed the design of novel therapeutic strategies based on biologic principals. Gene therapy is one such strategy. The underlying concept is to deliver to patients with OA genes that have products with antiarthritic properties. This results in the endogenous production of these products in a sustained and ultimately regulated fashion, thereby obviating the problems that exist with traditional methods of drug delivery. Synovium and articular cartilage are two attractive sites for the delivery of anti-OA genes. Preliminary experimental data support the use of these concepts.

Original languageEnglish (US)
Pages (from-to)333-344
Number of pages12
JournalRheumatic Disease Clinics of North America
Volume25
Issue number2
DOIs
StatePublished - 1999
Externally publishedYes

Fingerprint

Osteoarthritis
Genetic Therapy
Synovial Membrane
Articular Cartilage
Genes
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Rheumatology

Cite this

Potential treatment of osteoarthritis by gene therapy. / Evans, Christopher H; Robbins, P. D.

In: Rheumatic Disease Clinics of North America, Vol. 25, No. 2, 1999, p. 333-344.

Research output: Contribution to journalArticle

@article{da7ebba26cca48ffb98176dd156631f2,
title = "Potential treatment of osteoarthritis by gene therapy",
abstract = "Recent advances in understanding the biology of osteoarthritis have allowed the design of novel therapeutic strategies based on biologic principals. Gene therapy is one such strategy. The underlying concept is to deliver to patients with OA genes that have products with antiarthritic properties. This results in the endogenous production of these products in a sustained and ultimately regulated fashion, thereby obviating the problems that exist with traditional methods of drug delivery. Synovium and articular cartilage are two attractive sites for the delivery of anti-OA genes. Preliminary experimental data support the use of these concepts.",
author = "Evans, {Christopher H} and Robbins, {P. D.}",
year = "1999",
doi = "10.1016/S0889-857X(05)70071-5",
language = "English (US)",
volume = "25",
pages = "333--344",
journal = "Rheumatic Disease Clinics of North America",
issn = "0889-857X",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Potential treatment of osteoarthritis by gene therapy

AU - Evans, Christopher H

AU - Robbins, P. D.

PY - 1999

Y1 - 1999

N2 - Recent advances in understanding the biology of osteoarthritis have allowed the design of novel therapeutic strategies based on biologic principals. Gene therapy is one such strategy. The underlying concept is to deliver to patients with OA genes that have products with antiarthritic properties. This results in the endogenous production of these products in a sustained and ultimately regulated fashion, thereby obviating the problems that exist with traditional methods of drug delivery. Synovium and articular cartilage are two attractive sites for the delivery of anti-OA genes. Preliminary experimental data support the use of these concepts.

AB - Recent advances in understanding the biology of osteoarthritis have allowed the design of novel therapeutic strategies based on biologic principals. Gene therapy is one such strategy. The underlying concept is to deliver to patients with OA genes that have products with antiarthritic properties. This results in the endogenous production of these products in a sustained and ultimately regulated fashion, thereby obviating the problems that exist with traditional methods of drug delivery. Synovium and articular cartilage are two attractive sites for the delivery of anti-OA genes. Preliminary experimental data support the use of these concepts.

UR - http://www.scopus.com/inward/record.url?scp=0033036390&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033036390&partnerID=8YFLogxK

U2 - 10.1016/S0889-857X(05)70071-5

DO - 10.1016/S0889-857X(05)70071-5

M3 - Article

VL - 25

SP - 333

EP - 344

JO - Rheumatic Disease Clinics of North America

JF - Rheumatic Disease Clinics of North America

SN - 0889-857X

IS - 2

ER -